ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,006 GBX | +5.76% |
|
+9.05% | +12.28% |
| 03:40pm | ASTRAZENECA : UBS maintains a Sell rating | ZD |
| 03:22pm | Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
02:00am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
141.1
USD
Average target price
161.4
USD
Spread / Average Target
+14.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.28% | 219B | |
| +23.55% | 562B | |
| -5.03% | 358B | |
| +19.24% | 322B | |
| +8.31% | 297B | |
| +6.35% | 199B | |
| -9.90% | 196B | |
| -8.41% | 149B | |
| -5.08% | 146B | |
| +1.94% | 117B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca Faces Sluggish COVID-19 Antibody Rollout Over Effectiveness Woes
